Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 6/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15007994 | 1.00 | TACR1 (0.44) | TACR1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL19627472 | 1.00 | TACR1 (0.44) | TACR1SLC6A2SLC6A4SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL28273269 | 0.99 | TACR1 (0.43) | TACR1SLC6A2SLC6A4SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL28271740 | 0.99 | TACR1 (0.43) | TACR1SLC6A2SLC6A4SLC6A3HRH3 | |
| Hydrochloric Acid SCHEMBL28519089 | 0.99 | TACR1 (0.43) | TACR1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL11953966 | 0.95 | TACR1 (0.46) | TACR1DDB1CRBNOPRM1MAPT | |
| SCHEMBL26694866 | 0.89 | OPRM1 (0.45) | TACR1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL15026540 | 0.88 | TACR1 (0.47) | TACR1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL706214 | 0.88 | TACR1 (0.47) | TACR1SLC6A2SLC6A4SLC6A3HRH3 | |
| SCHEMBL15012678 | 0.87 | ALDH1A1 (0.42) | TACR1SLC6A2SLC6A4SLC6A3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025083472-A2 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025085815-A1 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4384522-A1 | SELECTIVE KRAS INHIBITORS | Erasca, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023018699-A1 | SELECTIVE KRAS INHIBITORS | ERASCA, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018699-A1 | SELECTIVE KRAS INHIBITORS | ERASCA, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | GENENTECH, INC. (US) | 2022-02-01 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | GENENTECH, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3055302-B1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| EP-2788349-A1 | KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2014-10-15 | — | — | EP | disclosed |
| WO-2013083604-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| WO-2013083604-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | WO | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| US-20130150343-A1 | KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2013-06-13 | — | — | US | disclosed |
| US-8232390-B2 | Pentacyclic indole derivatives as antiviral agents | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2012-07-31 | — | — | US | disclosed |
| US-20100009959-A1 | Pentacyclic Indole Derivatives as Antiviral Agents | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2010-01-14 | — | — | US | disclosed |
| EP-2027125-A1 | PENTACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007129119-A1 | PENTACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009959-A1 | Pentacyclic Indole Derivatives as Antiviral Agents | IDO1, IDO2, ZC3HAV1 | TACR1 494/4885SLC6A2 2569/4885SLC6A4 620/4885 |
| US-20200048197-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | TACR1 107/4885SLC6A2 525/4885SLC6A4 218/4885 |
| US-11236046-B2 | Substituted heterocyclic sulfonamide compounds useful as TRPA1 modulators | TRPA1, TRPV1, TRPV2 | TACR1 107/4885SLC6A2 525/4885SLC6A4 218/4885 |
| US-20130150343-A1 | KINASE INHIBITORS | MAPK1, MAP3K1, MAPK6 | TACR1 1218/4885SLC6A2 4330/4885SLC6A4 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.